NEW
HAVEN, Conn., Jan. 7, 2025
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today
announced that Vlad Coric, M.D., Chairman and Chief Executive
Officer, will present at the 43rd Annual J.P. Morgan
Healthcare Conference at The Westin St. Francis Hotel in
San Francisco, California, on
Monday, January 13, 2025, at
8:15 am (PT).
About Biohaven
Biohaven is a biopharmaceutical
company focused on the discovery, development, and
commercialization of life-changing treatments in key therapeutic
areas, including immunology, neuroscience, and oncology. Biohaven
is advancing its innovative portfolio of therapeutics, leveraging
its proven drug development experience and multiple proprietary
drug development platforms. Biohaven's extensive clinical and
nonclinical programs include Kv7 ion channel modulation for
epilepsy and mood disorders; extracellular protein degradation for
immunological diseases; TRPM3 antagonism for migraine and
neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory
disorders; glutamate modulation for OCD and SCA (spinocerebellar
ataxia); myostatin inhibition for neuromuscular and metabolic
diseases, including SMA and obesity; antibody recruiting bispecific
molecules and antibody drug conjugates for cancer. For more
information, visit www.biohaven.com.
Forward-looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The use of certain words,
including "continue", "plan", "will", "believe", "may", "expect",
"anticipate" and similar expressions, is intended to identify
forward-looking statements. Investors are cautioned that any
forward-looking statements, including statements regarding the
future development, timing and potential marketing approval and
commercialization of development candidates, are not guarantees of
future performance or results and involve substantial risks and
uncertainties. Actual results, developments and events may differ
materially from those in the forward-looking statements as a result
of various factors including: the expected timing, commencement and
outcomes of Biohaven's planned and ongoing clinical trials; the
timing of planned interactions and filings with the FDA; the timing
and outcome of expected regulatory filings; complying with
applicable U.S. regulatory requirements; the potential
commercialization of Biohaven's product candidates; and the
effectiveness and safety of Biohaven's product candidates.
Additional important factors to be considered in connection with
forward-looking statements are described in Biohaven's filings with
the Securities and Exchange Commission, including within the
sections titled "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations". The
forward-looking statements are made as of the date of this news
release, and Biohaven does not undertake any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Contact:
Jennifer
Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike
Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302345039.html
SOURCE Biohaven Ltd.
